Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Koloda, Yu.A.; Корсак, В. С.; Rozenson, Oleg; Anshina, M. B.; Sagamonova, K Yu; Баранов, И.И.; Yakovenko, S.A.; D’Hooghe, Thomas; Ershova, Anna S.; Lispi, Monica

doi:10.1016/j.bpobgyn.2022.01.009

Cited by 4 publications

(2 citation statements)

References 37 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While in some retrospective studies the addition of recombinant LH in poor prognosis patients seems to improve IVF results ( 35 , 36 ), no differences have been found in others ( 37 ). Numerous studies have been conducted on both agonist and antagonist cycles, comparing the inclusion of various doses (ranging from 37.5 IU to 150 IU ) of recombinant LH with recombinant FSH alone ( 3 – 6 , 13 , 23 - 30 ).…”

Section: Discussionmentioning

confidence: 96%

Comparison of the Administration of 150 or 75 IU of Recombinant LH in Agonist ICSI Cycles Stimulated with Recombinant FSH in Women Aged 35-39: A Comparative Study

Matorras,

Aspichueta,

Prieto

et al. 2023

JRI

View full text Add to dashboard Cite

Background: The purpose of the study was to assess whether the coadministration of 150 IU of recombinant LH instead of 75 IU in women aged 35-39 improves the results in agonist ICSI cycles stimulated with 300 IU of recombinant FSH. Methods: In this study, two ovarian stimulation protocols coexisted which were identical except in the administered dose of recombinant LH, for which some patients received 150 IU (n=231) and some received 75 IU (n=216). Both groups received 300 IU of recombinant FSH. Gonadotropins were reimbursed by the National Health System. Statistical analysis was performed by Student’s t test, χ2, and ANCOVA. Significance level was established at p=0.05. Results: The number of retrieved oocytes was slightly higher in the 300/150 group (9.06±5.53 vs. 8.61±5.11), but the differences were not significant. Results were similar with the number of metaphase II oocytes (7.18±4.86 vs. 6.72±4.72) and the number of fertilized oocytes (4.64±3.2 vs. 4.23±2.72). The per-transfer clinical pregnancy rates exhibited close similarity between both groups (32.84% vs. 32.46%), as did the per-transfer live birth rates (29.90% vs. 30.37%) and the implantation rate. The rate of hyperstimulation syndrome (OHSS) as well as the rate of cancellation due to OHHS risk was similar in both groups. There was also no difference in the miscarriage rate. When results were expressed by per started cycle or by oocyte pick-up, the results remained very similar in both groups. Conclusion: In women aged 35-39 undergoing ovarian stimulation with recombinant FSH in agonist cycles, the coadministration of 75 or 150 UI of recombinant LH did not influence pregnancy rates. However, a slight increase in the number of retrieved oocytes should not be disregarded.

show abstract

Section: Discussionmentioning

confidence: 96%

Comparison of the Administration of 150 or 75 IU of Recombinant LH in Agonist ICSI Cycles Stimulated with Recombinant FSH in Women Aged 35-39: A Comparative Study

Matorras,

Aspichueta,

Prieto

et al. 2023

JRI

View full text Add to dashboard Cite

show abstract

“…At the onset of each estrous cycle, there is a group of early antral follicles developed to one or more ovulatory follicle(s) continuously through follicles' selection and dominance. Recent interest has grown in the use of aspirated oocytes from antral ovarian follicles of live animals or slaughter-house ovaries for embryo production in vitro (Figure 2; Mohammed, 2006) (Mohammed, 2006;Mohammed, 2008;Mohammed, 2014a;Mohammed, 2014b;Mohammed et al, 2019;Ferré et al, 2020;Tian et al Follicle stimulating hormone (FSH), equine chorionic gonadotropin (eCG), luteinizing hormone (LH) and human chronic gonadotropin (hCG) were used for regulating ovarian follicle growth and ovulation in vivo (Mohammed et al, 2005;Mohammed et al, 2012a;Mohammed et al, 2012b;Mohammed et al, 2019;Koloda et al, 2022). In addition, culture conditions including gases, culture media and additives to culture media were used in vitro for regulating ovarian follicles' growth and development and oocytes' maturation (Mohammed et al, 2005;Salhab et al, 2011;Bahrami and Cottee, 2022).…”

Section: Introductionmentioning

confidence: 99%

Changes in Nucleus and Cytoplast During Oocyte Maturation: Involvement in Embryo Production

Zeidi¹,

Masruri²,

Mufarji³

et al. 2022

AAVS

View full text Add to dashboard Cite

Embryo production steps either in vivo or in vitro include oocyte meiotic maturation, fertilization and culture processes. Oocyte maturation is the first step for in vivo or in vitro embryo production. Oocyte maturation appears to be a simple step, but it is a very complex process. Maturation of oocytes include several changes at the cytoplasmic and nuclear levels that makes the oocytes able to undergo fertilization, pre-implantation and post-implantation embryo development. Oocyte meiotic maturation in vivo starts after LH hormone surge whereas it starts in vitro upon release of oocyte from the ovarian follicle. Rodent oocyte maturation lasts 15-17hr. whereas that of ruminant oocyte lasts 24hr. Several factors affect on oocytes maturation either in vitro or in vivo and therefore affect development of the resulting embryos. Because of the significance of oocyte maturation stage on further embryonic development, this review aims to discuss the knowledge of oocyte maturation and its effect on further development of embryos in vivo and in vitro.

show abstract

WITHDRAWN:Â Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35–40 years: A German database study

Bielfeld

Schwarze

Verpillat

et al. 2023

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Cited by 4 publications

References 37 publications

Comparison of the Administration of 150 or 75 IU of Recombinant LH in Agonist ICSI Cycles Stimulated with Recombinant FSH in Women Aged 35-39: A Comparative Study

Comparison of the Administration of 150 or 75 IU of Recombinant LH in Agonist ICSI Cycles Stimulated with Recombinant FSH in Women Aged 35-39: A Comparative Study

Changes in Nucleus and Cytoplast During Oocyte Maturation: Involvement in Embryo Production

WITHDRAWN:Â Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35–40 years: A German database study

Contact Info

Product

Resources

About